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Amir H Sepehripour*, Leanne Harling, Hutan Ashrafian, Roberto Casula and Thanos AthanasiouAbstract
Off-pump coronary artery bypass surgery (OPCAB) has been hypothesised to be beneficial in the high-risk patient
population undergoing re-operative coronary artery bypass graft surgery (CABG). In addition, this technique has
been demonstrated to provide subtle benefits in end-organ function including heart, lungs and kidney. The aims of
this study were to assess whether OPCAB is associated with a lower incidence of major adverse cardiovascular and
cerebrovascular events (MACCE) and other adverse outcomes in re-operative coronary surgery. Twelve studies,
incorporating 3471 patients were identified by systematic literature review. These were meta-analysed using
random-effects modelling. Primary endpoints were MACCE and other adverse outcomes including myocardial
infarction, stroke, renal dysfunction, low cardiac output state, respiratory failure and atrial fibrillation. A significantly
lower incidence of myocardial infarction, stroke, renal dysfunction, low cardiac output state, respiratory failure and atrial
fibrillation was observed with OPCAB (OR 0.58; 95% CI (confidence interval) [0.39-0.87]; OR 0.37; 95% CI [0.17-0.79]; OR 0.39;
95% CI [0.24-0.63]; OR 0.14; 95% CI [0.04-0.56]; OR 0.36; 95% CI [0.24-0.54]; OR 0.41; 95% CI [0.22-0.77] respectively).
Sub-group analysis using sample size, matching score and quality score was consistent with and reflected these significant
findings. Off-pump coronary artery bypass grafting reduces peri-operative and short-term major adverse outcomes in
patients undergoing re-operative surgery. Consequently we conclude that OPCAB provides superior organ protection and
a safer outcome profile in re-operative CABG.
Keywords: Re-operative, Coronary artery bypass grafting, Off-pump, Morbidity, Organ protectionIntroduction
The outcome profile of off-pump coronary artery bypass
surgery (OPCAB) has received much attention and
analysis. Whilst recent randomised trials have popularly
failed to demonstrate the beneficial effects of OPCAB in
comparison to on-pump coronary artery surgery
(ONCAB) with regards to mortality and major adverse
cardiovascular and cerebrovascular events (MACCE),
subtle benefits in end-organ function have been ob-
served [1,2]. However, the scepticism surrounding the
external validity of these trials, regarding selective pa-
tient enrolment and individual surgeon’s OPCAB ex-
perience still remains [3], and has heralded the need for* Correspondence: amir.sepehripour@gmail.com
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article, unless otherwise stated.closer analysis of registry data, providing a closer ‘real-
life’ representation of the population [4,5].
Off-pump coronary artery bypass surgery has been dem-
onstrated to reduce early mortality in re-operative coronary
artery bypass surgery (CABG) [6]. The aim of this study is
to address the question of whether OPCAB is associated
with a lower incidence of MACCE and other adverse out-
comes in re-operative coronary surgery.Review
Materials and methods
Search
A literature search was performed using PubMed,
EMBASE and Google Scholar up to May 2013 using the
MESH headings “coronary artery bypass, off-pump” and
“reoperation”. Studies in English comparing outcomesntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ONCAB were included (Table 1).
Outcomes of interest
Primary outcomes of interest in the OPCAB and ONCAB
groups were peri-operative and short-term (30-day)
MACCE and other adverse outcomes including myocardial
infarction, stroke, renal dysfunction, low cardiac output
state, respiratory failure and atrial fibrillation.
Analysis
Meta-analysis was performed in line with recommenda-
tions from PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) and MOOSE
(Meta-Analysis of Observational Studies in Epidemiology)
[7,8]. A random-effects model was used to analyse the data
and the odds ratio (OR) was used as the summary statistic
for binary data. Studies reporting zero events for both
OPCAB and ONCAB groups were excluded from the
meta-analysis.
Quantitative assessment of data validity and hetero-
geneity was performed using subgroup analysis for:
(1) Studies with a large sample size (≥50) in each cohort,
(2) Studies with a high degree of matching between
OPCAB and ONCAB groups (matching score ≥ 8), and
(3) Studies with a quality score ≥ 8.
Quality assessment
The studies were assessed in two ways: (1) using a
matching criteria score, and (2) using a quality assess-
ment score based on a modified Newcastle-Ottawa scale
(Table 2) [9]. The matching score was calculated for
each study by attributing one point for each pre-
operative characteristic for which no statistically signifi-
cant difference between the OPCAB and ONCAB
groups was observed (Table 3). The maximum matching
score was 37 and the median score was 8. Studies with a
score equal to or greater than 8 points were considered
as highly-matched studies and were subgroup analysed.
The modified Newcastle-Ottawa quality score was
calculated for each study using the subgroup criteria of
‘selection’, ‘comparability’ and ‘outcome assessment’, and
attributing stars to each study for these criteria (Table 4).
The maximum quality assessment score was 15 and the
median score was 8. Studies achieving a score equal to
or greater than 8 points were considered as high-quality
and were subgroup analysed.
Results
Twelve studies were identified by systematic search to
fulfil the inclusion criteria (Figure 1) [10-21]. These
studies included 3,471 patients, 1,286 of whom under-
went OPCAB and 2,185 underwent ONCAB. All studies
used standard cardiopulmonary bypass (CPB) circuitswithout the use of minimised systems. There were sev-
eral variations in myocardial arrest and cardioplegia
strategy within the ONCAB group. Of the 12 studies,
five used cold blood cardioplegia [12,14-16,21], one used
cold crystalloid [10], 2 used a combination of cold blood
and cold crystalloid [11,20] and one study used a com-
bination of cold blood, warm blood and hypothermic
ventricular fibrillation [19]. The majority of studies (5/9)
administered a combination of antegrade and retrograde
cardioplegia [11,14,16,17,21]. Two studies used only an
antegrade approach [19,20] and the remainder did not
specify their technique.
Primary outcomes
Myocardial infarction
The incidence of acute myocardial infarction was 3.03%
in the OPCAB group and 4.94% in the ONCAB group,
as reported by all studies. This reduction with OPCAB was
statistically significant using a random effects model
(OR 0.58; 95% CI (confidence interval) 0.39-0.87) (Figure 2).
No significant heterogeneity was found between the
studies.
Stroke
The incidence of stroke was 0.47% in the OPCAB group
and 2.38% in the ONCAB group, as reported by all stud-
ies. This reduction with OPCAB was statistically signifi-
cant using the random effects model (OR 0.37; 95% CI
0.17-0.79) (Figure 3), without significant heterogeneity
between the studies.
Renal failure
The incidence of acute renal failure with or without the
need for renal replacement therapy was 1.56% in the
OPCAB group and 5.22% in the ONCAB group, as re-
ported by ten studies [11,13-21]. This reduction with
OPCAB was statistically significant using the random ef-
fects model (OR 0.39; 95% CI 0.24-0.63) (Figure 4), with-
out significant heterogeneity between the studies.
Low cardiac output state
The incidence of the use of peri- or post-operative intra-
aortic balloon pump (IABP) secondary to a low cardiac out-
put state was 0.31% in the OPCAB group and 3.62% in the
ONCAB group, as reported by five studies [11,14,19-21].
This reduction with OPCAB was statistically significant
using the random effects model (OR 0.14; 95% CI 0.04-
0.56) (Figure 5), without significant heterogeneity between
the studies.
Respiratory failure
The incidence of acute respiratory failure or acute re-
spiratory distress syndrome (ARDS) was 3.03% in the
OPCAB group and 4.81% in the ONCAB group, as
Table 1 Pre-operative clinical characteristics for OPCAB and ONCAB groups
Study (N)
N Mean age Previous MI CHF/NYHA III/IV
Previous CVA/
TIA Hypertension Diabetes COPD
Renal
impairment
Mean ejection
fraction
Urgent/
Emergent
Off On Off On Off On Off On Off On Off On Off On Off On Off On Off On Off On
Alamanni
2001 (123)
[10]
53
(44%)
70
(56%)
66.4
(49–
77)
NS NS NS
9
(17%)
NS NS NS NS NS NS NS NS NS NS NS 0.56 NS
3
(5.6%)
NS
Bergsland
1998 (289)
[11]
105
(36%)
184
(64%)
66.0 65.7
76
(75.4%)
144
(78.7%)
24
(22.9%)
33
(18.1%)
12
(11.4%)
18
(9.8%)
89
(84.3%)
144
(78.7%)
25
(23.8%)
59
(32.2%)
31
(29.5%)
42
(23%)
1 (1%)
2
(1%)
0.45 0.47
8
(7.6%)
12
(6.5%)
Czerny
2003 (118)
[12]
44
(37%)
74
(63%)
66.9
± 8.9
67.1
± 7.7
NS NS NS NS NS NS NS NS NS NS NS NS NS NS
0.53 ±
0.14
0.57 ±
0.11
0
(0.0%)
0
(0.0%)
Dewey
2001 (432)
[13]
153
(35%)
279
(65%)
64.8
±
10.7
64.4
±
9.78
82
(53.6%)
153
(54.8%)
19
(12.4%)
34
(12.2%)
18
(11.8%)
26
(9.3%)
92
(60.1%)
184
(66%)
37
(24.2%)
71
(25.5%)
19
(12.4%)
26
(9.3%)
2
(1.3%)
2
(0.7%)
0.48 ±
0.11
0.47 ±
0.12
0
(0.0%)
0
(0.0%)
D’Ancona
2000 (581)
[14]
274
(47%)
307
(53%)
66.8
41–
85)
65.5
(37–
85)
NS NS
28
(10.2%)
21
(6.8%)
27
(9.9%)
32
(10.4%)
213
(77.7%)
229
(74.6%)
60
(21.9%)
82
(26.7%)
80
(29.2%)
73
(23.8%)
10
(3.8%)
2
(0.6%)
0.47
(0.13-
0.84)
0.48
(0.10-
0.76)
122
(44.5%)
171
(55.7%)
Gerli 2006
(132) [15]
41
(31%)
91
(69%)
67.0
± 8.9
65.0
± 7.6
28
(68.3%)
51
(56%)
13
(31.7%)
21
(23.1%)
3
(7.3%)
3
(3.3%)
NS NS
6
(14.6%)
12
(13.2%)
8
(19.5%)
13
(14.3%)
7
(17.1%)
9
(9.9%)
NS NS NS NS
Mishra
2008 (538)
[16]
332
(62%)
206
(38%)
60.4
± 5.8
61.2
± 6.1
153
(46.1%)
101
(49%)
23
(6.9%)
10
(4.9%)
12
(3.6%)
5
(2.4%)
159
(47.9%)
108
(52.4%)
108
(32.5%)
64
(31.1%)
25
(7.5%)
17
(8.2%)
5
(1.5%)
3
(1.4%)
0.43 ±
0.07
0.43 ±
0.07
118
(35.5%)
91
(44.2%)
Morris
2007 (771)
[17]
132
(17%)
639
(83%)
67.5
±
10.3
66.2
± 9.4
NS NS
37
(28%)
111
(17.4%)
34
(25.8%)
120
(18.8%)
NS NS
52
(39.4%)
203
(31.8%)
30
(22.7%)
96
(15%)
15
(11.4%)
38
(5.9%)
0.45 ±
0.13
0.46 ±
0.12
NS NS
Schutz
2001 (40)
[18]
20
(50%)
20
(50%)
63.2
± 9.3
67.1
± 6.6
NS NS NS NS NS NS
14
(70%)
12
(60%)
2
(10%)
5
(25%)
NS NS NS NS
0.53 ±
0.14
0.48 ±
0.15
0
(0.0%)
0
(0.0%)
Teodori
2000 (166)
[19]
54
(33%)
112
(67%)
64.7
± 8.5
62.7
± 8.6
NS NS
2
(3.7%)
1
(0.9%)
1
(1.8%)
10
(8.9%)
NS NS NS NS NS NS NS NS
0.54 ±
0.13
0.53 ±
0.14
20
(37%)
36
(32%)
Tugtekin
2006 (195)
[20]
35
(18%)
160
(82%)
66.9
± 7.9
66.0
± 8.1
17
(48.6%)
96
(40%)
1
(2.9%)
11
(6.9%)
NS NS NS NS
12
(34.3%)
59
(36.8%)
2
(5.7%)
10
(6.2%)
NS NS
0.52 ±
0.14
0.55 ±
0.16
12
(34.3%)
66
(41.3%)
Vohra 2008
(86) [21]
43
(50%)
43
(50%)
65.7
± 6.9
64.7
± 7.7
21
(48.8%)
23
(53.5%)
12
(27.9%)
18
(41.9%)
NS NS
27
(62.8%)
34
(79%)
10
(23.2%)
14
(32.5%)
4
(9.3%)
5
(11.6%)
1
(2.3%)
1
(2.3%)
NS NS
11
(25.6%)
9
(20.9%)
OPCAB – off-pump coronary artery bypass; ONCAB – on-pump coronary artery bypass; MI – myocardial infarction; CHF – congestive heart failure (Ejection Fraction <40%); NYHA – New York Heart Association;
CVA – cerebrovascular accident; TIA – transient ischaemic attack; COPD – chronic obstructive pulmonary disease; NS – not stated; (a) – statistical significance.
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Table 2 Quality checklist
Checklist for quality assessment and scoring of nonrandomized
studies
Selection 1. Assignment for treatment-Any criteria reported
(if yes, 1 star)?
2. How representative was the reference group (CPB)
in comparison to the general population for CABG?
(If yes, 1 star, no star if the patients were selected
or selection of group was not described.)
3. How representative was the treatment group (OPCAB)
in comparison to the general population for CABG?
(If drawn from the same community as the reference
group, 1 star, no star if drawn from a different source
or selection of group was not described.)
Comparability 4. Group comparable for 1, 2, 3, 4, 5. (If yes, 1 star was
assigned for each of these characteristics. No star
was assigned if the two groups differed.)
5. Group comparable for 6, 7, 8, 9, 10. (If yes, 1 star
was assigned for each of these characteristics. No
star was assigned if the two groups differed.)
Outcome
assessment
6. Clearly defined outcome of interest. (If yes, 1 star
for information ascertained by record linkage or
interview, no star if this information was not
reported.)
7. Follow-up (1 star if described.)
Comparability variables: (1) Age; (2) Gender;
(3) Hypertension; (4) Diabetes; (5) Ejection fraction;
(6) 3-Vessel Disease; (7) Left Main Stem Disease;
(8) Urgent or Emergent Operation; (9) Viability Studies;
(10) Surgeon or Hospital Volume
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with OPCAB was statistically significant using the random
effects model (OR 0.36; 95% CI 0.24-0.54) (Figure 6), with-
out significant heterogeneity between the studies.
A trial fibrillation
The incidence of post-operative atrial fibrillation was 5.05%
in the OPCAB group and 13.8% in the ONCAB group, as
reported by seven studies [10,12,14,16,17,20,21]. This
reduction with OPCAB was statistically significant using
the random effects model (OR 0.41; 95% CI 0.22-0.77)
(Figure 7), without significant heterogeneity between the
studies.
Subgroup analysis
Sample size
Seven studies had a large sample size (≥50) in each cohort
and were in this subgroup analysis [10,11,13,14,16,17,19].
Myocardial infarction was again significantly lower in
the OPCAB compared to the ONCAB group (2.99% vs.
4.28%; OR 0.63; 95% CI 0.41-0.99). Incidence of stroke
was again significantly lower with OPCAB (0.36% vs.
2.56% ONCAB; OR 0.28; 95% CI 0.11-0.69). Similarly,
the incidence of renal failure was again significantly
lower with OPCAB (1.36% vs. 5.51% ONCAB; OR 0.35;95% CI 0.20-0.60). Four studies [11,14,16,19] reported a
significantly reduced incidence of low cardiac output
states with OPCAB (0.27% vs. 3.78% ONCAB; OR 0.11;
95% CI 0.01-0.87). Five studies [11,13,14,16,19] reported
a significantly reduced incidence of respiratory failure/
ARDS with OPCAB (3.45% vs. 5.73% ONCAB; OR 0.35;
95% CI 0.23-0.52). Four studies [10,14,16,17] reported a
reduced incidence of atrial fibrillation with OPCAB
(4.35% vs. 12.24% ONCAB; OR 0.51; 95% CI 0.17-1.51).
Matching score and quality score
Eight studies were attributed a matching score of 8 or
greater and were included in this subgroup analysis
[11,13-15,17,19-21]. Nine studies were attributed a quality
score of 8 or greater and were included in this analysis
[11,13-15,17-21]. All studies with high matching score were
also found to have high quality score and therefore sub-
group analysis for matching and quality scores are consid-
ered together.
Myocardial infarction was again significantly lower in
the OPCAB compared to the ONCAB group (2.51% vs.
4.9%; OR 0.54; 95% CI 0.33-0.89). Incidence of stroke
was again significantly lower with OPCAB (0.6% vs.
2.64% ONCAB; OR 0.36; 95% CI 0.16-0.82). Similarly,
the incidence of renal failure was again significantly
lower with OPCAB (2.15% vs. 5.95% ONCAB; OR 0.40;
95% CI 0.24-0.68). Five studies [11,14,19-21] reported a
significantly reduced incidence of low cardiac output
states with OPCAB (0.48% vs. 4.35% ONCAB; OR 0.14;
95% CI 0.04-0.56). Five studies [11,13,14,19,20] reported
a significantly reduced incidence of respiratory failure/
ARDS with OPCAB (1.67% vs. 3.86% ONCAB; OR 0.33;
95% CI 0.18-0.59). Four studies [14,17,20,21] reported a
significantly reduced incidence of atrial fibrillation with
OPCAB (7.85% vs. 22.6% ONCAB; OR 0.33; 95% CI
0.16-0.70).
Comment
This meta-analysis demonstrates that OPCAB reduces the
incidence of major adverse events in the peri-operative and
short-term follow-up period. Significant reductions were
observed in the rates of myocardial infarction, stroke, renal
failure, low cardiac output state, respiratory failure and
atrial fibrillation. These observed beneficial effects of
OPCAB remained consistent in the subgroup analysis of
large sample size, high matching score and high quality
score studies.
Re-operative coronary artery surgery poses a great risk to
an already high-risk, older patient cohort with potentially
higher co-morbidity and end-organ disease. The challen-
ging technical aspects of the operation itself; including ster-
nal re-entry, epicardial adhesions, patent or diseased in-situ
grafts, more advanced coronary and aortic disease burden
and the sufficiency of myocardial protection are all the
Table 3 Study matching score
Study
Inclusion criteria Exclusion criteria
Matching criteria Matching score(Max 37)Off On Off On
Alamanni [10] A, F A NS NS NS 0
Bergsland [11] A, K A, K NS NS 8, 13, 15, 16, 18, 20, 21,25, 28, 29, 31 11
Czerny [12] A, B, K A, B, K D, G D, G 2, 8, 10, 26, 32, 33 6
Dewey [13] A, F, G A E, F A, B, E, F 2, 5, 8, 13, 14, 15, 16, 18, 20, 21, 22 11
D’Ancona [14] A A NS NS 1, 2, 3, 5, 8, 12, 15, 16, 18, 19, 20, 21, 24, 25, 28, 29 16
Gerli [15] A, B A, B NS NS 2, 3, 9, 13, 16, 18, 20, 21 8
Mishra [16] A, I, K A, I, K D, E, I, J J NS 0
Morris [17] A, K A, K NS NS 2, 3, 5, 6, 7, 8, 10, 13, 15, 16, 18, 19, 20, 21, 31, 37 16
Schutz [18] A, I A, K D, B D, B 2, 3, 8, 15, 16, 17, 18 7
Teodori [19] A A NS NS 2, 3, 8, 21, 22, 26, 28, 31 8
Tugtekin [20] A, K A, K J J 2, 3, 8, 9, 10, 11, 13, 16, 20, 22, 24, 25, 26 13
Vohra [21] A, B, C A, B, C D, F D, F 3, 6, 7, 9, 10, 12, 13, 15, 16, 17, 18, 20, 22, 24, 29, 30, 31, 32 18
Inclusion Criteria: (A) Re-do CABG, (B) Elective operation; (C) Previous CPB CABG; (D) Single-vessel disease; (E) Multi-vessel disease; (F) High-risk for CPB;
(G) Significant medical co-morbidities; (H) Age >75; (I) Symptomatic CAD not managed by medical therapy; (J) Angiographically non-calcified non-intramyocardial
distal LAD and patent LIMA; (K) Discretion of the surgeon.
Exclusion Criteria: (A) High-risk for CPB; (B) Significant medical co-morbidities; (C) Religious convictions that precluded blood transfusion; (D) Emergency operation;
(E) Haemodynamic instability; (F) Cardiogenic shock; (G) Unstable angina; (H) Age <75; (I) Poor quality of distal coronary target vessels; (J) Discretion of
the surgeon.
Matching Criteria: (1) Number of patients; (2) Age; (3) Gender; (4) Body Mass Index; (5) Congestive Heart Failure; (6) CCS Class III/IV; (7) NYHA Class III/IV;
(8) Ejection Fraction; (9) Ejection Fraction <30%; (10) Number of Diseased Vessels; (11) 3-Vessel Disease; (12) Left Main Stem Disease; (13) Previous MI; (14) Previous
Valve Repair/Replacement; (15) Hypertension; (16) Diabetes; (17) Hypercholestrolaemia; (18) Renal Impairment/Failure; (19) Pre-Op Dialysis; (20) COPD;
(21) Cerebrovascular Disease; (22) Peripheral Vascular Disease; (23) Elective Operation; (24) Urgent Operation; (25) Emergency Operation; (26) Time from Previous
CABG; (27) Frequency of Patent, Significantly Stenosed (>70%) or Occluded Previous Grafts; (28) Calcified Ascending Aorta; (29) Pre-Op IV GTN; (30) Pre-Op IV Inotropes;
(31) Pre-Op IABP; (32) EuroSCORE; (33) Parsonnet Score; (34) Cleveland Clinic Score; (35) Viability Studies; (36) Hospital Volume; (37) Surgeon Volume.
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risk nature of the operation. These complexities of re-
operative coronary surgery have inevitably not permit-
ted the inclusion of these patients in randomised trials.
A very clear spectrum of difficulty is observed in different
patients undergoing re-operative coronary artery surgery,Table 4 Study quality score
Study
Quality assessment –
selection
Quality assess
comparab
1 2 3 4
Alamanni [10] * * * -
Bergsland [11] * * * ***
Czerny [12] * * * **
Dewey [13] * * * ****
D’Ancona [14] * * * *****
Gerli [15] * * * ****
Mishra [16] * * * -
Morris [17] * * * *****
Schutz [18] * * * *****
Teodori [19] * * * ***
Tugtekin [20] * * * ****
Vohra [21] * * * ****
*: the number of points each study is given in each of the categories.providing a spectrum of challenges. Baseline co-morbidities,
ventricular function and the quality of target coronary ves-
sels are some of the factors affecting the decision to under-
take OPCAB, the risk of conversion to ONCAB, the degree
of target vessel revascularisation, the effect on target organ
preservation and ultimately the outcome profile [6].ment –
ility
Quality assessment –
outcome assessment Quality assessment -
score (out of 15)
5 6 7
- * - 4
* * - 8
- * * 7
- * - 8
** * - 11
- * - 8
- * - 4
* * - 10
- * * 10
- * * 8
** * * 11
** * * 11
436 studies 
indentified in initial 
search
139 studies identified 
through references 
and related articles
575 studies screened
489 studies excluded 
by title and abstract 
review
86 full-text studies 
assessed for 
eligibility
73 studies excluded 
on evaluation of 
study methodology
12 studies included in 
meta-analysis
Figure 1 Search strategy.
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ging, prompting scepticism regarding surgeon experi-
ence and expertise, does provide very clear protection
for the heart, the brain and other organs. Firstly, avoid-
ing manipulation of the aorta and previous bypass grafts
in OPCAB reduces the risk of coronary and cerebral em-
bolisation. Secondly, providing sufficient myocardial pro-
tection in the setting of extensive coronary disease is
challenging and often requires a retrograde approach.
Utilisation of intra-coronary shunts in OPCAB reduce
the ischaemic time and consequent myocardial stunning.
Thirdly, the avoidance of extra-corporeal membrane cir-
culation eliminates the systemic inflammatory response
observed with CPB, protecting predominantly the lungs
and the kidneys as well as all other organs. Finally, the
elimination of the CPB-induced coagulopathy may de-
crease the need for transfusion and potentially reduce
re-exploration for bleeding [6]. However, it is crucial to
consider that, given the spectrum of difficulty observedwith re-operative coronary surgery and the factors af-
fecting the decision to undertake OPCAB, appropriate
patient selection is of paramount importance, whereby
OPCAB is not necessarily the most appropriate tech-
nique for all patients.
In a recent analysis of the Society of Thoracic Surgeons
Adult Cardiac Surgery Database by Ghanta et al. [22],
outcomes of 72,431 patients undergoing isolated reopera-
tive coronary artery bypass grafting were observed over
the period 2000 to 2009. Risk-adjusted rates of stroke de-
creased from 1.9% in 2000 to 1.6% in 2009 (relative risk re-
duction −16.5%, p < 0.001); of renal failure decreased from
5.5% to 4.9% (−15.4%, p < 0.004); of prolonged ventilation
increased from 11.6% to 15.3% (31.4%, p = 0.532); and of
atrial fibrillation increased from 19.0% to 19.9% (4.8%,
p = 0.532); amongst other outcome measures of morbidity
observed. The OPCAB outcome measures of our study
compare favourably with those of Ghanta and colleagues,
the largest report to date analysing isolated reoperative
CABG.
OPCAB has been demonstrated to reduce early mor-
tality in re-operative CABG [6]. The aim of this study
was to explore beyond these effects on mortality and at-
tempt to ascertain whether OPCAB can reduce MACCE
and other adverse outcomes in re-operative CABG by
means of providing more superior organ protection. All
of the studied outcome measures were demonstrated to
be significantly reduced with OPCAB, emphasising the
superior organ protection provided by the technique.
Limitations
The issue of surgeon experience and expertise with
OPCAB surgery has been a source of much debate and
criticism [2]. This challenging technique has a very pro-
nounced learning curve and requires time and experi-
ence in order for the outcomes to be comparable. The
same concept applies for re-operative surgery. Whilst
not under the same degree of scepticism, owing to the
lack of randomised trials, re-operation itself is an even
bigger challenge, requiring particular experience and is
more time consuming. In order to improve the validity
and reliability of the results of this study, surgeon ex-
perience in both OPCAB and re-operative CABG will
need to be accounted and adjusted for.
A further limitation of this study is the short follow-up
period of analysis. We have demonstrated significant
reduction in 30-day adverse outcomes using OPCAB,
however in order to allow generalisation of these results
regarding the outcome profile of OPCAB in re-operative
CABG, mid- and long-term analysis of adverse outcomes
are required.
A further limitation of this study which is required to be
taken into account is that OPCAB is not necessarily the
most appropriate technique for all patients undergoing re-
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Figure 2 Myocardial infarction for OPCAB and ONCAB groups.
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Figure 3 Stroke for OPCAB and ONCAB groups.
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Figure 4 Renal failure for OPCAB and ONCAB groups.
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Figure 5 Low cardiac output state for OPCAB and ONCAB groups.
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Figure 7 Atrial fibrillation for OPCAB and ONCAB groups.
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to be superior in the setting of suitable coronary target ves-
sels, a low risk of conversion to ONCAB and minimal re-
quirement for manipulation of the heart, allowing for target
vessel revascularisation.Conclusions
Off-pump coronary artery bypass grafting reduces peri-
operative and short-term major adverse outcomes in pa-
tients undergoing re-operative coronary artery surgery.
These outcomes include myocardial infarction, stroke, renal
failure, low cardiac output state, respiratory failure and
new-onset atrial fibrillation. Consequently we conclude that
OPCAB provides superior organ protection and a safer out-
come profile in re-operative CABG.
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